Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
HKD 1.39
(-0.71%)
HKD 1.39
(-0.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 385.21 Million CNY | -14.04% |
| 2022 | 494.15 Million CNY | 11.27% |
| 2021 | 444.09 Million CNY | 6.45% |
| 2020 | 417.18 Million CNY | 7.14% |
| 2019 | 389.37 Million CNY | 0.46% |
| 2018 | 387.59 Million CNY | 3.61% |
| 2017 | 374.1 Million CNY | 3.19% |
| 2016 | 362.52 Million CNY | 20.95% |
| 2015 | 299.74 Million CNY | -11.5% |
| 2014 | 338.68 Million CNY | 20.14% |
| 2013 | 281.9 Million CNY | 25.47% |
| 2012 | 224.67 Million CNY | 33.55% |
| 2011 | 168.23 Million CNY | 46.91% |
| 2010 | 114.51 Million CNY | 25.22% |
| 2009 | 91.45 Million CNY | 45.61% |
| 2008 | 62.8 Million CNY | 17.68% |
| 2007 | 53.36 Million CNY | 29.52% |
| 2006 | 41.2 Million CNY | -10.69% |
| 2005 | 46.13 Million CNY | -9.63% |
| 2004 | 51.05 Million CNY | -11.73% |
| 2003 | 57.83 Million CNY | 31.83% |
| 2002 | 43.86 Million CNY | 30.22% |
| 2001 | 33.68 Million CNY | -7.24% |
| 2000 | 36.31 Million CNY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 93.63 Million CNY | 0.0% |
| 2024 Q1 | 93.63 Million CNY | -31.02% |
| 2023 Q3 | 115.04 Million CNY | 21.63% |
| 2023 Q1 | 79.39 Million CNY | -38.68% |
| 2023 Q2 | 94.58 Million CNY | 19.13% |
| 2023 FY | 424.76 Million CNY | -14.04% |
| 2023 Q4 | 135.74 Million CNY | 17.99% |
| 2022 FY | 494.15 Million CNY | 11.27% |
| 2022 Q3 | 146.34 Million CNY | 61.48% |
| 2022 Q4 | 129.47 Million CNY | -11.53% |
| 2022 Q1 | 127.7 Million CNY | -24.53% |
| 2022 Q2 | 90.62 Million CNY | -29.03% |
| 2021 Q1 | 108.14 Million CNY | -5.09% |
| 2021 Q3 | 90.49 Million CNY | 18.7% |
| 2021 FY | 444.09 Million CNY | 6.45% |
| 2021 Q4 | 169.2 Million CNY | 86.98% |
| 2021 Q2 | 76.24 Million CNY | -29.5% |
| 2020 Q1 | 111.59 Million CNY | 59.69% |
| 2020 Q2 | 91.92 Million CNY | -17.63% |
| 2020 Q3 | 99.72 Million CNY | 8.49% |
| 2020 Q4 | 113.94 Million CNY | 14.26% |
| 2020 FY | 417.18 Million CNY | 7.14% |
| 2019 FY | 389.37 Million CNY | 0.46% |
| 2019 Q4 | 69.88 Million CNY | -37.91% |
| 2019 Q3 | 112.54 Million CNY | 13.43% |
| 2019 Q1 | 107.73 Million CNY | 45.59% |
| 2019 Q2 | 99.21 Million CNY | -7.9% |
| 2018 FY | 387.59 Million CNY | 3.61% |
| 2018 Q3 | 106.17 Million CNY | 16.04% |
| 2018 Q4 | 73.99 Million CNY | -30.31% |
| 2018 Q2 | 91.5 Million CNY | -21.06% |
| 2018 Q1 | 115.91 Million CNY | 65.25% |
| 2017 Q2 | 87.68 Million CNY | -20.36% |
| 2017 Q3 | 106.17 Million CNY | 21.08% |
| 2017 FY | 374.1 Million CNY | 3.19% |
| 2017 Q4 | 70.14 Million CNY | -33.93% |
| 2017 Q1 | 110.1 Million CNY | 34.85% |
| 2016 FY | 362.52 Million CNY | 20.95% |
| 2016 Q4 | 81.64 Million CNY | -17.7% |
| 2016 Q3 | 99.21 Million CNY | 29.38% |
| 2016 Q2 | 76.67 Million CNY | -26.97% |
| 2016 Q1 | 104.99 Million CNY | 109.44% |
| 2015 FY | 299.74 Million CNY | -11.5% |
| 2015 Q1 | 85.58 Million CNY | -26.97% |
| 2015 Q2 | 77.66 Million CNY | -9.26% |
| 2015 Q3 | 86.36 Million CNY | 11.2% |
| 2015 Q4 | 50.12 Million CNY | -41.96% |
| 2014 Q2 | 64.36 Million CNY | -15.1% |
| 2014 FY | 338.68 Million CNY | 20.14% |
| 2014 Q4 | 117.19 Million CNY | 44.12% |
| 2014 Q3 | 81.32 Million CNY | 26.35% |
| 2014 Q1 | 75.8 Million CNY | -7.29% |
| 2013 Q3 | 65.81 Million CNY | 12.96% |
| 2013 FY | 281.9 Million CNY | 25.47% |
| 2013 Q1 | 76.04 Million CNY | -2.79% |
| 2013 Q2 | 58.26 Million CNY | -23.38% |
| 2013 Q4 | 81.77 Million CNY | 24.24% |
| 2012 Q4 | 78.22 Million CNY | 16.19% |
| 2012 Q2 | 79.11 Million CNY | 67.46% |
| 2012 FY | 224.67 Million CNY | 33.55% |
| 2012 Q1 | 47.24 Million CNY | -26.46% |
| 2012 Q3 | 67.32 Million CNY | -14.9% |
| 2011 Q1 | 23.62 Million CNY | -23.53% |
| 2011 Q2 | 31.59 Million CNY | 33.74% |
| 2011 Q3 | 48.76 Million CNY | 54.32% |
| 2011 Q4 | 64.24 Million CNY | 31.75% |
| 2011 FY | 168.23 Million CNY | 46.91% |
| 2010 Q1 | 19.39 Million CNY | 0.0% |
| 2010 FY | 114.51 Million CNY | 25.22% |
| 2010 Q3 | 25.44 Million CNY | -34.4% |
| 2010 Q4 | 30.89 Million CNY | 21.44% |
| 2010 Q2 | 38.78 Million CNY | 99.97% |
| 2009 FY | 91.45 Million CNY | 45.61% |
| 2009 Q2 | 20.65 Million CNY | 0.0% |
| 2008 FY | 62.8 Million CNY | 17.68% |
| 2007 FY | 53.36 Million CNY | 29.52% |
| 2006 FY | 41.2 Million CNY | -10.69% |
| 2005 FY | 46.13 Million CNY | -9.63% |
| 2004 FY | 51.05 Million CNY | -11.73% |
| 2003 FY | 57.83 Million CNY | 31.83% |
| 2002 FY | 43.86 Million CNY | 30.22% |
| 2001 FY | 33.68 Million CNY | -7.24% |
| 2000 FY | 36.31 Million CNY | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 24.42 Million HKD | -1477.207% |
| Grand Pharmaceutical Group Limited | 3.86 Billion HKD | 90.022% |
| Extrawell Pharmaceutical Holdings Limited | 35.52 Million HKD | -984.294% |
| Wai Yuen Tong Medicine Holdings Limited | 353.93 Million HKD | -8.839% |
| Qianhai Health Holdings Limited | 17.1 Million HKD | -2152.468% |
| Lee's Pharmaceutical Holdings Limited | 590.99 Million HKD | 34.819% |
| Essex Bio-Technology Limited | 1.22 Billion HKD | 68.655% |
| Tongfang Kontafarma Holdings Limited | 503.46 Million HKD | 23.487% |
| PuraPharm Corporation Limited | 216.62 Million HKD | -77.823% |
| SSY Group Limited | 1.98 Billion HKD | 80.552% |
| JBM (Healthcare) Limited | 163.87 Million HKD | -135.066% |
| Jacobson Pharma Corporation Limited | 287.34 Million HKD | -34.059% |
| China Resources Pharmaceutical Group Limited | 29.35 Billion HKD | 98.688% |